597 related articles for article (PubMed ID: 34732890)
1. Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs.
Yarmarkovich M; Marshall QF; Warrington JM; Premaratne R; Farrel A; Groff D; Li W; di Marco M; Runbeck E; Truong H; Toor JS; Tripathi S; Nguyen S; Shen H; Noel T; Church NL; Weiner A; Kendsersky N; Martinez D; Weisberg R; Christie M; Eisenlohr L; Bosse KR; Dimitrov DS; Stevanovic S; Sgourakis NG; Kiefel BR; Maris JM
Nature; 2021 Nov; 599(7885):477-484. PubMed ID: 34732890
[TBL] [Abstract][Full Text] [Related]
2. Targeting of intracellular oncoproteins with peptide-centric CARs.
Yarmarkovich M; Marshall QF; Warrington JM; Premaratne R; Farrel A; Groff D; Li W; di Marco M; Runbeck E; Truong H; Toor JS; Tripathi S; Nguyen S; Shen H; Noel T; Church NL; Weiner A; Kendsersky N; Martinez D; Weisberg R; Christie M; Eisenlohr L; Bosse KR; Dimitrov DS; Stevanovic S; Sgourakis NG; Kiefel BR; Maris JM
Nature; 2023 Nov; 623(7988):820-827. PubMed ID: 37938771
[TBL] [Abstract][Full Text] [Related]
3. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy.
Marcu A; Bichmann L; Kuchenbecker L; Kowalewski DJ; Freudenmann LK; Backert L; Mühlenbruch L; Szolek A; Lübke M; Wagner P; Engler T; Matovina S; Wang J; Hauri-Hohl M; Martin R; Kapolou K; Walz JS; Velz J; Moch H; Regli L; Silginer M; Weller M; Löffler MW; Erhard F; Schlosser A; Kohlbacher O; Stevanović S; Rammensee HG; Neidert MC
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858848
[TBL] [Abstract][Full Text] [Related]
4. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
5. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
Roerden M; Nelde A; Walz JS
Front Immunol; 2019; 10():3004. PubMed ID: 31921218
[TBL] [Abstract][Full Text] [Related]
6. Structural principles of peptide-centric chimeric antigen receptor recognition guide therapeutic expansion.
Sun Y; Florio TJ; Gupta S; Young MC; Marshall QF; Garfinkle SE; Papadaki GF; Truong HV; Mycek E; Li P; Farrel A; Church NL; Jabar S; Beasley MD; Kiefel BR; Yarmarkovich M; Mallik L; Maris JM; Sgourakis NG
Sci Immunol; 2023 Dec; 8(90):eadj5792. PubMed ID: 38039376
[TBL] [Abstract][Full Text] [Related]
7. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.
Freudenmann LK; Marcu A; Stevanović S
Immunology; 2018 Jul; 154(3):331-345. PubMed ID: 29658117
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy.
Yang P; Meng M; Zhou Q
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188558. PubMed ID: 33933558
[TBL] [Abstract][Full Text] [Related]
9. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
[TBL] [Abstract][Full Text] [Related]
10. Translating Immunopeptidomics to Immunotherapy-Decision-Making for Patient and Personalized Target Selection.
Fritsche J; Rakitsch B; Hoffgaard F; Römer M; Schuster H; Kowalewski DJ; Priemer M; Stos-Zweifel V; Hörzer H; Satelli A; Sonntag A; Goldfinger V; Song C; Mahr A; Ott M; Schoor O; Weinschenk T
Proteomics; 2018 Jun; 18(12):e1700284. PubMed ID: 29505699
[TBL] [Abstract][Full Text] [Related]
11. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.
Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641
[TBL] [Abstract][Full Text] [Related]
12. Structural principles of peptide-centric Chimeric Antigen Receptor recognition guide therapeutic expansion.
Sun Y; Florio TJ; Gupta S; Young MC; Marshall QF; Garfinkle SE; Papadaki GF; Truong HV; Mycek E; Li P; Farrel A; Church NL; Jabar S; Beasley MD; Kiefel BR; Yarmarkovich M; Mallik L; Maris JM; Sgourakis NG
bioRxiv; 2023 May; ():. PubMed ID: 37292750
[TBL] [Abstract][Full Text] [Related]
13. Bispecific antibodies targeting mutant
Douglass J; Hsiue EH; Mog BJ; Hwang MS; DiNapoli SR; Pearlman AH; Miller MS; Wright KM; Azurmendi PA; Wang Q; Paul S; Schaefer A; Skora AD; Molin MD; Konig MF; Liu Q; Watson E; Li Y; Murphy MB; Pardoll DM; Bettegowda C; Papadopoulos N; Gabelli SB; Kinzler KW; Vogelstein B; Zhou S
Sci Immunol; 2021 Mar; 6(57):. PubMed ID: 33649101
[TBL] [Abstract][Full Text] [Related]
14. Targeting Neoantigens for Personalised Immunotherapy.
Pritchard AL
BioDrugs; 2018 Apr; 32(2):99-109. PubMed ID: 29516371
[TBL] [Abstract][Full Text] [Related]
15. Enhancing cholangiocarcinoma immunotherapy with adoptive T cells targeting HLA-restricted neoantigen peptides derived from driver gene mutations.
Panya A; Thepmalee C; Sawasdee N; Saengmuang S; Luangwattananun P; Yenchitsomanus PT
Biomed Pharmacother; 2023 Dec; 168():115827. PubMed ID: 37939617
[TBL] [Abstract][Full Text] [Related]
16. Proteogenomic discovery of cancer antigens: Neoantigens and beyond.
Kanaseki T; Tokita S; Torigoe T
Pathol Int; 2019 Sep; 69(9):511-518. PubMed ID: 31397525
[TBL] [Abstract][Full Text] [Related]
17. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
18. Apparent Lack of
Kemps PG; Zondag TC; Steenwijk EC; Andriessen Q; Borst J; Vloemans S; Roelen DL; Voortman LM; Verdijk RM; van Noesel CJM; Cleven AHG; Hawkins C; Lang V; de Ru AH; Janssen GMC; Haasnoot GW; Franken KLMC; van Eijk R; Solleveld-Westerink N; van Wezel T; Egeler RM; Beishuizen A; van Laar JAM; Abla O; van den Bos C; van Veelen PA; van Halteren AGS
Front Immunol; 2019; 10():3045. PubMed ID: 31998317
[TBL] [Abstract][Full Text] [Related]
19. Rapid T cell-based identification of human tumor tissue antigens by automated two-dimensional protein fractionation.
Beckhove P; Warta R; Lemke B; Stoycheva D; Momburg F; Schnölzer M; Warnken U; Schmitz-Winnenthal H; Ahmadi R; Dyckhoff G; Bucur M; Jünger S; Schueler T; Lennerz V; Woelfel T; Unterberg A; Herold-Mende C
J Clin Invest; 2010 Jun; 120(6):2230-42. PubMed ID: 20458140
[TBL] [Abstract][Full Text] [Related]
20. Identification of prostate-specific G-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy.
Matsueda S; Wang M; Weng J; Li Y; Yin B; Zou J; Li Q; Zhao W; Peng W; Legras X; Loo C; Wang RF; Wang HY
PLoS One; 2012; 7(9):e45756. PubMed ID: 23029225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]